Contact UsInvestorsCareersMediaScienceContact Us
HomeScienceOpen InnovationPartnership With Regeneron For UK Biobank Exome Sequencing

Partnership With Regeneron For UK Biobank Exome Sequencing

In January 2018, we became part of a collaboration along with four other pharmaceutical companies that aims to speed up the exome sequencing of 500,000 UK participants, to help researchers and patients around the world.1

Sequencing a person’s whole genome is time-consuming and expensive. That’s why some researchers choose to sequence the 1% of protein-coding genes in a genome, known as the exome.²

Through exome sequencing, researchers can begin to identify mutations in known genes that can aid diagnosis, identify new targets for treatment and in the longer term lead to potential new therapies.2

Between 2006 and 2010, the UK Biobank recruited 500,000 people who gave blood, urine and saliva samples for widespread research use.Participants also filled out an elaborate questionnaire about their habits and conditions and agreed to have their health data collected both retrospectively and updated on an ongoing basis, approximately once each year.3

The retrospective data allows researchers to look at history of disease while the prospective data will allow researchers to understand what might contribute to the development of new cases of disease.

Announced in January 2018, Regeneron Pharmaceuticals brought together AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer who will each provide $10 million funding to enable the Regeneron Genetics Center (RGC) to expedite the sequencing as part of one of the industry's most ambitious 'pre-competitive' research efforts.This collaboration builds upon the original sequencing initiative started with Regeneron and GSK who committed to analysing data from the first 50,000 UK Biobank participants.1

The best part of this massive medical endeavour? By the end of 2020 the collected data will be open to any researcher who submits an application approved by a UK Biobank committee.Any results are required to be released back to the UK Biobank, as the aim of the resource is to improve the health of future generations.3

“ We are proud to contribute to the advancement of genetic research by joining this important initiative, which is poised to provide new insights into human health and could help guide the research efforts of Pfizer and our consortium partners as we continually work towards our shared mission of bringing new therapies to patients in need.”

Morten Sogaard, Vice President, Target Science & Technologies at Pfizer Inc.



In 2015 we joined ADDoPT, a 4 year £20.4 million collaborative project between government, pharmaceutical companies, SME's and academia.


Medical Research Council Collaboration

Between 2014 and 2018, Pfizer collaborated with the UK-based Medical Research Council to make available a ‘virtual library’ of compounds for use by academic researchers in the UK.


  1. Regeneron, 8th January 2018, Regeneron Forms Consortium of Leading Life Sciences Companies to Accelerate Largest Widely-Available 'Big Data' Human Sequencing Resource with UK Biobank

  2. NCBI, 2nd July 2015, Exome Sequencing: Current and Future Perspectives

  3. UK Biobank, Updated 21 March 2018, About the UK Biobank

  4. Genome Web, 8th January 2018, Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples

    PP-UNP-GBR-2917 / November 2022
    Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.